Premier in diagnostics deal with DiaSys:
This article was originally published in Clinica
Executive Summary
US group purchasing organisation Premier has signed a two-year deal to access part of DiaSys's line of diagnostics for its 1,600-member hospitals. The deal, signed in May 2002, covers a new class of products developed by Waterbury, Connecticut-based DiaSys, the R/S series lab workstations. The device monitors patients with cancer, kidney disease and expectant mothers. Microscopic urine testing is also available from the device. Premier, which is owned by 200 hospitals and healthcare systems, distributes $14 billion-worth of supplies and equipment to its members annually.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.